DOCSLIB.ORG

Adaptive, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Adaptive, Dose-Finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease ORIGINAL ARTICLE Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer Disease Robert A. Lenz, MD, PhD,* Yili L. Pritchett, PhD,* Scott M. Berry, PhD,w Daniel A. Llano, MD, PhD,* Shu Han, PhD,* Donald A. Berry, PhD,wz Carl H. Sadowsky, MD,y8 Walid M. Abi-Saab, MD,* and Mario D. Saltarelli, MD, PhD* concept, and dose-finding study adaptively randomized patients to Abstract: ABT-089, an a4b2 neuronal nicotinic receptor partial ago- receive ABT-089 (5, 10, 15, 20, 30, or 35 mg once daily) or placebo for nist, was evaluated for efficacy and safety in mild to moderate Alz- 12 weeks. The primary efficacy endpoint was the Alzheimer’s Disease heimer disease patients receiving stable doses of acetylcholinesterase Assessment Scale, cognition subscale (ADAS-Cog) total score. A inhibitors. This phase 2 double-blind, placebo-controlled, proof-of- Bayesian response-adaptive randomization algorithm dynamically assigned allocation probabilities based on interim ADAS-Cog total scores. A normal dynamic linear model for dose-response relationships Received for publication June 26, 2014; accepted January 30, 2015. and a longitudinal model for predicting final ADAS-cog score were From the *AbbVie Inc., North Chicago, IL; wBerry Consultants, LLC, Austin, TX; zMD Anderson Cancer Center, University of Texas, employed in the algorithm. Stopping criteria for futility or success were Houston, TX; yDivision of Neurology, Nova Southeastern defined. The futility stopping criterion was met, terminating the study University, Fort Lauderdale, FL; and 8Palm Beach Neurology, with 337 patients randomized. No dose-response relationship was West Palm Beach, FL, USA. observed and no dose demonstrated statistically significant improve- Present address: Robert A. Lenz, MD, PhD, Amgen, Thousand Oaks, ment over placebo on ADAS-Cog or any secondary endpoint. ABT- CA. 089 was well tolerated at all dose levels. When administered as Present address: Yili L. Pritchett, PhD, Astellas Pharma Global Develop- adjunctive therapy to acetylcholinesterase inhibitors, ABT-089 was not ment Inc., Northbrook, IL. efficacious in mild to moderate Alzheimer disease. The adaptive study Present address: Daniel A. Llano, MD, PhD, Beckman Institute, University of Illinois, Urbana, IL. design enabled the examination of a broad dose range, enabled rapid Present address: Shu Han, PhD, Hospira Inc., Lake Forest, IL. determination of futility, and reduced patient exposure to noneffica- Present address: Walid M. Abi-Saab, MD, Shire AG, Nyon, cious doses of the investigational compound. Switzerland. Present address: Mario D. Saltarelli, MD, PhD, Mallinckrodt Phar- Key Words: Alzheimer disease, neuronal nicotinic receptor, partial maceuticals, Hazelwood, MO. agonist, adaptive trial design Supported by AbbVie Inc. (CT.gov registry number: NCT00555204; http:// clinicaltrials.gov/ct2/show/NCT00555204? term = m06-876&rank = 2). (Alzheimer Dis Assoc Disord 2015;29:192–199) AbbVie was involved in the study design, collection, and interpretation of data, and writing, reviewing, and approving the publication. R.A.L. is a former employee of Abbott (now AbbVie) and holds AbbVie stock. Y.L.P. is a former employee of Abbott (now Abb- Vie), and holds AbbVie stock. S.M.B. is the President and coowner lzheimer disease (AD) is a progressive, neuro- of Berry Consultants, LLC. Berry Consultants, LLC, consults with degenerative disorder that accounts for 60% to 70% of AbbVie and other pharmaceutical and medical device companies A 1 regarding the design of clinical trials. D.A.L. is a former employee progressive cognitive impairment in the elderly. Because of of Abbott (now AbbVie). S.H. is a former employee of Abbott (now the modest efficacy of available treatments, much attention AbbVie) and holds AbbVie stock. D.A.B. is a member of the has been focused on developing better AD medications. University of Texas MD Anderson Cancer Center and is coowner However, these endeavors have resulted in more failures of Berry Consultants, LLC. Berry Consultants, LLC, consults with AbbVie and other pharmaceutical and medical device companies than successes, and no new therapies have been approved regarding the design of clinical trials. C.H.S. has participated on for AD since 2003. Numerous recent clinical failures in AD speaker bureaus for Novartis, Forest Laboratories, and Accera. He have led some companies to abandon pursuit of treatments is also a member of the Pharmaceutical Advisory Board for Eli Lilly for this indication.2 Novel trial designs to aid in the and the Scientific Advisory Board for the Alzheimer’s Drug Dis- covery Foundation. He received payment from Abbott (now development of AD agents are therefore needed. AbbVie) as an investigator in the trial. W.M.A.-S. is a former Among the reasons for failed AD trials is ineffective employee of Abbott (now AbbVie), and is currently employed by trial design and execution, often resulting in inadequate Shire AG. He holds equity in AbbVie, Novartis, Pfizer, and Shire evaluation of a drug’s full dose range.3,4 Adaptive trial and is an AbbVie patent holder. M.D.S. is a former employee of Abbott (now AbbVie), Shire, and Pfizer. He is currently employed designs that use accumulating data to continuously modify by Mallinckrodt Pharmaceuticals and receives various forms of specific trial aspects offer particular advantages over tra- compensation from Mallinckrodt. M.D.S. holds equity in AbbVie ditional, resource-intensive, often inefficient phase 2 trials. and Mallinckrodt, and is an inventor on AbbVie and Pfizer patents. Predefined decision rules and frequent interim efficacy Reprints: Robert A. Lenz, MD, PhD, One Amgen Center Drive, Mail Stop 38-2-B, Thousand Oaks, CA 91320 (e-mail: robertlenz00@ evaluations can efficiently assess success and failure. gmail.com). Response-adaptive randomization uses interim data to Supplemental Digital Content is available for this article. Direct URL allocate patients to more informative treatment arms, citations appear in the printed text and are provided in the HTML allowing efficient evaluation of a wide range of doses.5,6 and PDF versions of this article on the journal’s Website, www.alzheimerjournal.com. Employing these tools can achieve proof-of-concept (POC) Copyright r 2015 Wolters Kluwer Health, Inc. All rights reserved. and determine an effective dose range in a single trial. 192 | www.alzheimerjournal.com Alzheimer Dis Assoc Disord Volume 29, Number 3, July–September 2015 Copyright r 2015 Wolters Kluwer Health, Inc. All rights reserved. Alzheimer Dis Assoc Disord Volume 29, Number 3, July–September 2015 Adaptive, Dose-finding Phase 2 Trial of ABT-089 ABT-089 is a partial agonist of the a4b2 neuronal randomized (after 12 interim adaptive calculations). This nicotinic receptor (NNR).7 Multiple pharmacologically and adjustment was made based on the recommendation of the functionally distinct NNR subtypes mediate the broad Data Monitoring Committee and was due to the higher range of effects of nicotine.8–11 Several preclinical and than usual placebo response seen in the first 12 interim clinical studies have demonstrated that NNR agonists, efficacy evaluations. Given the observations in the first 12 including a4b2 NNR agonists, improve cognitive perform- interim assessments, the Data Monitoring Committee sug- ance.12–14 Given the loss of cholinergic afferent terminals gested that increasing the sample size of the placebo group characteristic of the progression of AD, it was predicted could result in a more precise estimate of the mean change that the administration of an agonist at a4b2 receptors in the ADAS-Cog total score for placebo-treated patients would provide benefit above that seen with acetylcholines- and therefore a more precise estimation of treatment effect. terase inhibitors (AChEIs) alone. The current study was The sponsor was not involved in or informed of this deci- designed to assess the safety and efficacy of ABT-089 in sion. A normal dynamic linear model (NDLM) was used to broad dose range in patients with mild to moderate AD as guide the estimation of the dose-response relationship an adjunctive agent to donepezil. It is a POC study as well among dose groups.16 The NDLM was used because it is as a dose-finding study. To gain efficacy, response-adaptive flexible enough to capture both monotonic and non- randomization design was utilized. monotonic dose-response relationships. The objective of the adaptive algorithm was to identify METHODS the ED90 (lowest dose of ABT-089 that resulted in 90% of the maximal effect compared with placebo) and the minimum Standard Protocol Approvals, Registrations, and effective dose (MED; lowest dose of ABT-089 that resulted in Patient Consent at least a 1.75-point ADAS-Cog improvement over placebo in The study protocol was approved by the independent mean change from baseline). The reason for choosing a 1.75- ethics committee or institutional review board at each study point improvement as the minimum clinically meaningful site, and the study was conducted in accordance with the difference was that this amount was considered to be 75% of ethical principles that have their origin in the Declaration of the monotherapy effect of donepezil on mild to moderate AD Helsinki.15 All patients (or their legally acceptable repre- patients, which is approximately 2.33 units on the ADAS-Cog sentatives) provided written informed consent. Clinical trial total score as reported by the Cochrane Collaboration registration (clinicaltrials.gov): NCT00555204. (2006).17 As an adjunctive therapy, it was estimated that the effectofABT-089wouldbeless,andwasestimatedtobe75% Study Design of the effect of donepezil alone. Stopping criteria were assessed This was a phase 2, randomized, double-blind, pla- once 150 patients were randomized, and at each subsequent cebo-controlled, multicenter (41 US sites) study using a biweekly interim analysis. Biweekly interims are operationally Bayesian response-adaptive randomization design5,6 con- easy to implement, as opposed to subject thresholds, with no ducted from November 2007 to June 2009. Subjects were on loss in efficiency.
Load more

Recommended publications
  • Nicotinic Receptors in Neurodegeneration
    Send Orders of Reprints at [email protected] 298 Current Neuropharmacology, 2013, 11, 298-314 Nicotinic Receptors in Neurodegeneration Inmaculada Posadas, Beatriz López-Hernández and Valentín Ceña* Unidad Asociada Neurodeath. CSIC-Universidad de Castilla-La Mancha, Departamento de Ciencias Médicas. Albacete, Spain and CIBERNED, Instituto de Salud Carlos III, Spain Abstract: Many studies have focused on expanding our knowledge of the structure and diversity of peripheral and central nicotinic receptors. Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of pentameric ligand-gated ion channels, which include GABA (A and C), serotonin, and glycine receptors. Currently, 9 alpha (2-10) and 3 beta (2-4) subunits have been identified in the central nervous system (CNS), and these subunits assemble to form a variety of functional nAChRs. The pentameric combination of several alpha and beta subunits leads to a great number of nicotinic receptors that vary in their properties, including their sensitivity to nicotine, permeability to calcium and propensity to desensitize. In the CNS, nAChRs play crucial roles in modulating presynaptic, postsynaptic, and extrasynaptic signaling, and have been found to be involved in a complex range of CNS disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), schizophrenia, Tourette´s syndrome, anxiety, depression and epilepsy. Therefore, there is growing interest in the development of drugs that modulate nAChR functions with optimal benefits and minimal adverse effects. The present review describes the main characteristics of nAChRs in the CNS and focuses on the various compounds that have been tested and are currently in phase I and phase II trials for the treatment of neurodegenerative diseases including PD, AD and age-associated memory and mild cognitive impairment.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Evidence of Efficacy for TC-1734 (AZD3480) in the Treatment of Cognitive Impairment in Older Subjects Geoffrey C
    Evidence of Efficacy for TC-1734 (AZD3480) in the Treatment of Cognitive Impairment in Older Subjects Geoffrey C. Dunbar, Iphigenia L. Koumenis, Ramana V. Kuchibhatla, James K. Wamsley Targacept, Inc., Winston-Salem, NC, USA Introduction Demographics Numerous pre-clinical animal models indicated TC-1734 (AZD3480) Patient disposition is given in Table 1 and baseline characteristics in Table 2. had a beneficial effect on cognition (1). Early work in man likewise Table 1 provided evidence TC-1734 (AZD3480) might have a beneficial effect Patient Disposition: Pre-screened= 373 Table 2: Baseline on cognition, especially attention and episodic memory (2). The Screened=224 Characteristics present study assessed the efficacy of TC-1734 (AZD3480) in an older TC- TC- population with subjective and objectively defined Age Associated Placebo Total Placebo TC-25mg TC-50 Memory Impairment (AAMI). 25mg 50mg Age 65.3 64.8 65.3 Methodology Randomized 66 59 68 193 (years) M:F 31:35 19:40 36:32 Completed 58 53 57 168 Volunteers aged 50-80 years with subjective memory impairment and WMS-R who scored at least 1 standard deviation below that seen in healthy Dropout AE 3 4 4 11 15.8 15.8 15.7 young adults on the Wechsler Memory Scale – Revised, Paired PAL Associate Learning Test, were randomized into a double blind fixed dose, placebo controlled, parallel group study. Subjects did not meet criteria for MCI. Treatment was for 16 weeks and subjects received 25 mg, 50 mg Table 3: Most Frequent Adverse Event by Treatment Group TC-1734 (AZD3480) or placebo. Routine safety measures were taken.
    [Show full text]
  • WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/001643 Al 7 January 2016 (07.01.2016) P O P C T (51) International Patent Classification: (74) Agents: GILL JENNINGS & EVERY LLP et al; The A61P 25/28 (2006.01) A61K 31/194 (2006.01) Broadgate Tower, 20 Primrose Street, London EC2A 2ES A61P 25/16 (2006.01) A61K 31/205 (2006.01) (GB). A23L 1/30 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/GB20 15/05 1898 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 29 June 2015 (29.06.2015) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (26) Publication Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 141 1570.3 30 June 2014 (30.06.2014) GB TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 1412414.3 11 July 2014 ( 11.07.2014) GB (84) Designated States (unless otherwise indicated, for every (71) Applicant: MITOCHONDRIAL SUBSTRATE INVEN¬ kind of regional protection available): ARIPO (BW, GH, TION LIMITED [GB/GB]; 39 Glasslyn Road, London GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, N8 8RJ (GB).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Selective Α4β2 Nicotinic Acetylcholine Receptor Agonists Target
    Neuropsychopharmacology (2011) 36, 1366–1374 & 2011 American College of Neuropsychopharmacology. All rights reserved 0893-133X/11 $32.00 www.neuropsychopharmacology.org Selective a4b2 Nicotinic Acetylcholine Receptor Agonists Target Epigenetic Mechanisms in Cortical GABAergic Neurons Ekrem Maloku1, Bashkim Kadriu1, Adrian Zhubi1, Erbo Dong1, Fabio Pibiri1, Rosalba Satta1 and Alessandro Guidotti*1 1 The Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA Nicotine improves cognitive performance and attention in both experimental animals and in human subjects, including patients affected by neuropsychiatric disorders. However, the specific molecular mechanisms underlying nicotine-induced behavioral changes remain unclear. We have recently shown in mice that repeated injections of nicotine, which achieve plasma concentrations comparable to those reported in high cigarette smokers, result in an epigenetically induced increase of glutamic acid decarboxylase 67 (GAD67) expression. Here we explored the impact of synthetic a4b2 and a7 nAChR agonists on GABAergic epigenetic parameters. Varenicline (VAR), a high-affinity partial agonist at a4b2 and a lower affinity full agonist at a7 neuronal nAChR, injected in doses of 1–5 mg/kg/s.c. twice daily for 5 days, elicited a 30–40% decrease of cortical DNA methyltransferase (DNMT)1 mRNA and an increased expression of GAD67 mRNA and protein. This upregulation of GAD67 was abolished by the nAChR antagonist mecamylamine. Furthermore, the level of MeCP2 binding to GAD67 promoters was significantly reduced following VAR administration. This effect was abolished when VAR was administered with mecamylamine. Similar effects on cortical DNMT1 and GAD67 expression were obtained after administration of A–85380, an agonist that binds to a4b2 but has negligible affinity for a3b4 or a7 subtypes containing nAChR.
    [Show full text]
  • 2 Agonist ABT-894 in Adults with ADHD
    Neuropsychopharmacology (2013) 38, 405–413 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of a4b2 Agonist ABT-894 in Adults with ADHD ,1 1 1 1 1,3 1,4 Earle E Bain* , Weining Robieson , Yili Pritchett , Tushar Garimella , Walid Abi-Saab , George Apostol , 2 1,5 James J McGough and Mario D Saltarelli 1 2 Clinical Development, Abbott Laboratories, Abbott Park, IL, USA; Semel Institute for Neuroscience and Behavior, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA Dysregulation of the neuronal nicotinic acetylcholine receptor (NNR) system has been implicated in attention-deficit/hyperactivity disorder (ADHD), and nicotinic agonists improve attention across preclinical species and humans. Hence, a randomized, double-blind, placebo-controlled, crossover study was designed to determine the safety and efficacy of a novel a4b2 NNR agonist (ABT-894 (3-(5,6- dichloro-pyridin-3-yl)-1(S),5 (S)-3,6-diazabicyclo[3.2.0]heptane)) in adults with ADHD. Participants (N 243) were randomized to one ¼ of four dose regimens of ABT-894 (1, 2, and 4 mg once daily (QD)) or 4 mg twice daily (BID) or the active comparator atomoxetine (40 mg BID) vs placebo for 28 days. Following a 2-week washout period, participants crossed over to the alternative treatment condition (active or placebo) for an additional 28 days. Primary efficacy was based on an investigator-rated Conners’ Adult ADHD Rating Scale (CAARS:Inv) Total score at the end of each 4-week treatment period. Additional secondary outcome measures were assessed.
    [Show full text]
  • Cognitive Enhancers
    Cognitive enhancers Memory enhancers are often referred to as "smart drugs", "study drugs",[1] "smart nutrients", "cognitive enhancers", "brain enhancers" or in the scientific literature as nootropics.[2] They are drugs that are purported to improve human cognitive abilities.[3][4] The term covers a broad range of substances including drugs, nutrients and herbs with purported cognitive enhancing effects. The word nootropic was coined in 1964 by Dr. Corneliu E. Giurgea, derived from the Greek words noos, or "mind," and tropein meaning "to bend/turn". Typically, nootropics are thought to work by altering the availability of the brain's supply of neurochemicals (neurotransmitters, enzymes, and hormones), by improving the brain's oxygen supply, or by stimulating nerve growth. However the efficacy of nootropic substances in most cases has not been conclusively determined. This is complicated by the difficulty of defining and quantifying cognition and intelligence. Contents 1 Availability 2 Examples 2.1 Stimulants 2.2 Replenishing and increasing neurotransmitters 2.2.1 Cholinergics 2.2.1.1 Piracetam 2.2.1.2 Aniracetam 2.2.1.3 Other cholinergics 2.2.1.4 Acetylcholinesterase inhibitors 2.2.2 Dopaminergics 2.2.3 Serotonergics 2.3 Anti-depression, adaptogenic (antistress), and mood stabilization 2.4 Brain function and improved oxygen supply 2.5 Purported memory enhancement and learning improvement 2.6 Nerve growth stimulation and brain cell protection 2.7 Recreational drugs with purported nootropic effects 2.8 Dietary nootropics 2.9 Other nootropics 2.9.1 Contentious or possibly unsafe nootropics 3 See also 3.1 Brain and neurology 3.2 Thought and thinking (what nootropics are used for) 3.3 Health 4 References 5 External links Availability Currently there are several drugs on the market that improve memory, concentration, planning and reduce impulsive behavior.
    [Show full text]
  • Drug Delivery System for Use in the Treatment Or Diagnosis of Neurological Disorders
    (19) TZZ __T (11) EP 2 774 991 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 10.09.2014 Bulletin 2014/37 C12N 15/86 (2006.01) A61K 48/00 (2006.01) (21) Application number: 13001491.3 (22) Date of filing: 22.03.2013 (84) Designated Contracting States: • Manninga, Heiko AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 37073 Göttingen (DE) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO •Götzke,Armin PL PT RO RS SE SI SK SM TR 97070 Würzburg (DE) Designated Extension States: • Glassmann, Alexander BA ME 50999 Köln (DE) (30) Priority: 06.03.2013 PCT/EP2013/000656 (74) Representative: von Renesse, Dorothea et al König-Szynka-Tilmann-von Renesse (71) Applicant: Life Science Inkubator Betriebs GmbH Patentanwälte Partnerschaft mbB & Co. KG Postfach 11 09 46 53175 Bonn (DE) 40509 Düsseldorf (DE) (72) Inventors: • Demina, Victoria 53175 Bonn (DE) (54) Drug delivery system for use in the treatment or diagnosis of neurological disorders (57) The invention relates to VLP derived from poly- ment or diagnosis of a neurological disease, in particular oma virus loaded with a drug (cargo) as a drug delivery multiple sclerosis, Parkinsons’s disease or Alzheimer’s system for transporting said drug into the CNS for treat- disease. EP 2 774 991 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 774 991 A1 Description FIELD OF THE INVENTION 5 [0001] The invention relates to the use of virus like particles (VLP) of the type of human polyoma virus for use as drug delivery system for the treatment or diagnosis of neurological disorders.
    [Show full text]
  • Activities of Nicotinic Acetylcholine Receptors Modulate Neurotransmission and Synaptic Architecture
    NEURAL REGENERATION RESEARCH December 2014,Volume 9,Issue 24 www.nrronline.org INVITED REVIEW Activities of nicotinic acetylcholine receptors modulate neurotransmission and synaptic architecture Akira Oda1, Hidekazu Tanaka2 1 CNS Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 2-26-1, Muraoka-higashi, Fujisawa, Kanagawa 251-8555, Japan 2 Laboratory of Pharmacology, Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1, Noji-higashi, Kusatsu, Shiga 525-8577, Japan Abstract Corresponding author: The cholinergic system is involved in a broad spectrum of brain function, and its failure has Hidekazu Tanaka, M.D., Ph.D., been implicated in Alzheimer’s disease. Acetylcholine transduces signals through muscarinic Laboratory of Pharmacology, Department and nicotinic acetylcholine receptors, both of which influence synaptic plasticity and cognition. of Biomedical Sciences, College of Life However, the mechanisms that relate the rapid gating of nicotinic acetylcholine receptors to per- Sciences, Ritsumeikan University, sistent changes in brain function have remained elusive. Recent evidence indicates that nicotinic [email protected]. acetylcholine receptors activities affect synaptic morphology and density, which result in per- sistent rearrangements of neural connectivity. Further investigations of the relationships between doi:10.4103/1673-5374.147943 nicotinic acetylcholine receptors and rearrangements of neural circuitry in the central nervous http://www.nrronline.org/ system may help understand the pathogenesis of Alzheimer’s disease. Accepted: 2014-11-03 Key Words: cholinergic system; nicotinic acetylcholine receptors (nAChRs); Alzheimer’s disease (AD); synaptic transmission; synaptic plasticity; synaptic morphology; dendritic spine remodeling; cognition Funding: Tanaka H is supported by the Takeda Science Foundation and JSPS KAKENHI Grant Number 19590247.
    [Show full text]
  • 3518.Full.Pdf
    3518 • The Journal of Neuroscience, March 3, 2010 • 30(9):3518–3530 Behavioral/Systems/Cognitive Prefrontal ␤2 Subunit-Containing and ␣7 Nicotinic Acetylcholine Receptors Differentially Control Glutamatergic and Cholinergic Signaling Vinay Parikh,1 Jinzhao Ji,1 Michael W. Decker,2 and Martin Sarter1 1Department of Psychology and Neuroscience Program, University of Michigan, Ann Arbor, Michigan 48109-1043, and 2Neuroscience Research, Abbott Laboratories, Abbott Park, Illinois 60064-6125 One-second-long increases in prefrontal cholinergic activity (“transients”) were demonstrated previously to be necessary for the incor- poration of cues into ongoing cognitive processes (“cue detection”). Nicotine and, more robustly, selective agonists at ␣4␤2* nicotinic acetylcholine receptors (nAChRs) enhance cue detection and attentional performance by augmenting prefrontal cholinergic activity. The present experiments determined the role of ␤2-containing and ␣7 nAChRs in the generation of prefrontal cholinergic and glutamatergic transients in vivo. Transients were evoked by nicotine, the ␣4␤2* nAChR agonist ABT-089 [2-methyl-3-(2-(S)-pyrrolindinylmethoxy) pyridine dihydrochloride], or the ␣7 nAChR agonist A-582941 [2-methyl-5-(6-phenyl-pyridazin-3-yl)-octahydro-pyrrolo[3,4-c]pyrrole]. Transientswererecordedinmicelacking␤2or␣7nAChRsandinratsafterremovalofthalamicglutamatergicormidbraindopaminergic inputs to prefrontal cortex. The main results indicate that stimulation of ␣4␤2* nAChRs evokes glutamate release and that the presence of thalamic afferents is necessary for the generation of cholinergic transients. ABT-089-evoked transients were completely abolished in mice lacking ␤2* nAChRs. The amplitude, but not the decay rate, of nicotine-evoked transients was reduced by ␤2* knock-out. Con- versely, in mice lacking the ␣7 nAChR, the decay rate, but not the amplitude, of nicotine-evoked cholinergic and glutamatergic transients was attenuated.
    [Show full text]